Literature DB >> 1531245

Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy.

S M Haffner1, S E Moss, B E Klein, R Klein.   

Abstract

Recently, considerable data have suggested that lipoprotein (a) [Lp(a)] is a strong independent risk factor for coronary heart disease. Since Lp(a) is increased in both insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), this study examined the relationship of Lp(a) concentrations to coronary heart disease (CHD) mortality in the 4-year follow-up of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). Twenty-four older-onset subjects and 11 younger-onset subjects who died of CHD (cases) before the age of 70 were matched by age, gender, and type of diabetes to subjects who remained alive (controls). The distribution and mean levels of Lp(a) in the cases and controls were very similar, suggesting a lack of association between Lp(a) concentrations and CHD mortality. Although the number of subjects was small, caution should be used in extrapolating results on Lp(a) relationships in nondiabetic subjects to diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531245     DOI: 10.1016/0026-0495(92)90152-z

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay.

Authors:  R W Evans; S S Sankey; B A Hauth; K Sutton-Tyrrell; M I Kamboh; L H Kuller
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

2.  Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

Authors:  Qibin Qi; Tsegaselassie Workalemahu; Cuilin Zhang; Frank B Hu; Lu Qi
Journal:  Eur Heart J       Date:  2011-09-06       Impact factor: 29.983

3.  Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.

Authors:  A D MBewu; P N Durrington; M I Mackness; L Hunt; W H Turkie; J E Creamer
Journal:  Br Heart J       Date:  1994-04

4.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

5.  Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Santamaria; J D Best
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

6.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

7.  Lipoprotein (a) and vascular disease in diabetic patients.

Authors:  R W James; M Boemi; C Sirolla; L Amadio; P Fumelli; D Pometta
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

8.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

9.  Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism.

Authors:  Carmine Gazzaruso; Adriana Garzaniti; Stefano Giordanetti; Colomba Falcone; Pietro Fratino
Journal:  Cardiovasc Diabetol       Date:  2002-11-22       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.